Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin.
about
New small molecules targeting apoptosis and cell viability in osteosarcomaStrategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling.miR-382 inhibits tumor growth and enhance chemosensitivity in osteosarcoma.A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells.A novel androstenedione derivative induces ROS-mediated autophagy and attenuates drug resistance in osteosarcoma by inhibiting macrophage migration inhibitory factor (MIF).Targeting protein kinases to reverse multidrug resistance in sarcoma.Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery.Acute and Chronic Hyperglycemia Elicit JIP1/JNK-Mediated Endothelial Vasodilator Dysfunction of Retinal Arterioles.Cytotoxic effects of 15d-PGJ2 against osteosarcoma through ROS-mediated AKT and cell cycle inhibition.Recent advances in delivery of drug-nucleic acid combinations for cancer treatmentCell death sensitization of leukemia cells by opioid receptor activationConventional osteosarcoma of the mandible successfully treated with radical surgery and adjuvant chemotherapy after responding poorly to neoadjuvant chemotherapy: a case report.JNK, p38, ERK, and SGK1 Inhibitors in Cancer.A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery.Role of C-Jun N-terminal Kinase in Hepatocellular Carcinoma Development.Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug resistance.
P2860
Q28547760-EAE750C1-CB2B-424B-B1FE-D652FCA41E64Q33757127-BED4FD3C-0370-4293-97B3-9443CBC9B0FFQ34619410-74BBB69D-2A46-476F-91EC-E987035960E1Q35263202-91A6B505-9C70-4B7D-9C91-0C83C9A355C2Q35679492-F83C0F82-0772-4106-A123-6EAD1274C6DDQ36527950-CA61445A-B757-4627-8901-9434F1A8D325Q37235596-1C6782D3-DC41-448A-B4BE-8A25544EEEA6Q37242111-29573018-A8F2-4AC3-9F09-2DF57E0874A3Q37718423-47D4A0AF-83D5-4CC3-B685-0070E4806ADCQ38102522-EE63A268-341C-4C36-93D6-5FAF8ABBBB0EQ39158015-43A46C88-6A35-4296-8524-24D4AAB12E07Q41212765-EA8DFD49-F72E-4884-ABB9-9803C743316CQ47265464-BC255E67-5668-44A4-A872-BB5D57DDAE30Q47900854-FB289BF7-D6F0-48DC-AE1A-77C548BABD78Q51653926-FBBCDA46-BBD5-4F30-BA5B-D6AEED7C3FF9Q55710454-511EF1A5-E7C7-4035-8E24-B283F5D88B28
P2860
Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin.
@en
Targeting JNK-interacting-protein-1
@nl
type
label
Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin.
@en
Targeting JNK-interacting-protein-1
@nl
prefLabel
Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin.
@en
Targeting JNK-interacting-protein-1
@nl
P2093
P2860
P356
P1433
P1476
Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin.
@en
P2093
Anne-Marie Cleton-Jansen
Barend J van Royen
Gert-Jan J L Kaspers
Henk M W Verheul
Jantine Posthumadeboer
Jeroen A M Beliën
Marco N Helder
Pim W van Egmond
Renée X de Menezes
Victor W van Beusechem
P2860
P304
P356
10.18632/ONCOTARGET.600
P407
P577
2012-10-01T00:00:00Z